Marco Ruella, M.D., Luca Paruzzo, M.D., Emeline R. Chong, B.A., Elise A. Chong, M.D., Daniel J. Landsburg, M.D., Sunita D. Nasta, M.D., Pooja Devi, M.D., +12 , and Stephen J. Schuster, M.D. Ten-Year Outcomes after CAR T-Cell Therapy for B-Cell Lymphomas , N Engl J Med, 394(2): 2026,2440-2448
Fang CY, MacFarlane AW 4th, Fung HCH, Khan N, Barta SK, Hasler JS, Ballard HJ, Landsburg DJ, Nasta SD, Schuster SJ, Khanal R, Fisher RI, Cohen AD, Svoboda J, Campbell KS Investigating Associations Between Psychological Distress and Changes in Peripheral Blood Monocytes in Patients With CLL/SLL Managed With Active Surveillance. , Cancer Med., 15(5): 2026,e71903
Thomas CJ, Myers CS, Chung J, Landsburg D, Nasta SD, Svoboda J, Chong EA, Schuster SJ, Carter J, Cook M, Tomasulo E, Elghawy O, LaRiviere M, Hubbeling H, Plastaras JP, Rook AH, Villasenor-Park J, Ruella M, Kim E, Barta SK. Clinical features and outcomes of patients with non-erythrodermic mycosis fungoides with high blood tumor burden. , Blood Neoplasia. 2026 Apr 25;3(3):., 3(3): 2026,100239
Patel K, Vose JM, Nasta SD, Brown JR, Maddocks KJ, Woyach JA, Shah NN, Fakhri B, Tessoulin B, Ma S, Jagadeesh D, Lech-Maranda E, Coombs CC, Patel MR, Rhodes JM, Ujjani C, Hoffmann MS, Cheah CY, Munir T, Lewis D, Scarfò L, Eyre TA, Alencar A, Cohen JB, Zelenetz AD, Tsai DE, Li M, Bian Y, Abada P, Balbas M, Zinzani PL. Pirtobrutinib, a highly selective, noncovalent (reversible) BTKi in R/R marginal zone lymphoma: phase 1/2 BRUIN study. , Blood Adv., 10(7): 2026,2441-2451
Landsburg DJ, Musoke N, Gentile C, Brooks TR, Nasta SD, Barta SK, Carter JS, Chong EA, Svoboda J, Schuster SJ, Thomas CJ, Tomasulo EB, Cook MR, Morrissette JJD, Caimi PF, Hill BT. Prognostic impact of TP53 alterations in cases of newly diagnosed large B-cell lymphoma. , Leukemia, 40(3): 2026,694-697
Ward RE, Dave N, Pai EL, Colbourn R, Banihashemi A, Nasta SD, Babatunde VD. Methotrexate-associated Peripheral Neuropathy on 18 F-FDG PET/CT and MRI Masquerading as Neurolymphomatosis. , Clin Nucl Med., 51(2): 2026,e144-e146
Jiang C, Hoover T, Baron J, Han X, Li B, Gao Y, Kim M, Hubbeling H, Chong EA, Carter J, Svoboda J, Schuster SJ, Landsburg DJ, Nasta SD, Plastaras J, LaRiviere M. Long Term Results of Proton Therapy in Adult Infradiaphragmatic Lymphoma. , Int J Part Ther., 19: 2026,101304
Carrie Thompson 1, Marek Trněný 2, Franck Morschhauser 3, Gilles Salles 4, Patrick M Reagan 5, Mark Hertzberg 6, Huilai Zhang 7, Catherine Thieblemont 8, Bei Hu 9, Gustavo Fonseca 10, Won Seog Kim 11, Maurizio Martelli 12, Amitkumar Mehta 13, Avrita Singh 14, Mark Yan 15, Jamie Hirata 14, Matthew Sugidono 14, Calvin Lee 14, Jeff P Sharman 16, Neha Mehta-Shah 17, Christopher R Flowers 18, Hervé Tilly 19, Neil Chua 20, René-Olivier Casasnovas 21, Fiona Miall 22, Tae Min Kim 23, Xavier Cheng-Hong Tsai 24, Sunita Nasta 25, Seung Tae Lee 26, Jonathan W Friedberg 5 PROs vs clinician-reported adverse events in a large clinical trial: findings from the phase 3 POLARIX study , Blood, 147(3): 2026,254-265
Nikita K. Dave, Paola Carvajal, Jordan S. Carter, Michael Cook, Colin Thomas, Donald E. Tsai, Stephen J. Schuster, James N. Gerson, Stefan K. Barta, Jakub Svoboda, Elise A. Chong, Daniel J. Landsburg, Sunita D. Nasta Prolonged Methotrexate, Temozolomide and Rituximab in Secondary Central Nervous System Lymphoma , American Society of Clinical Oncology Annual Meeting, Chicago, IL.: 2025
Saishravan Shyamsundar, Larissa Borys, Sheila Pierson, Mateo Sarmiento Bustamante, Adam Bagg, Mary Jo Lechowicz, Daisy Alapat, Amy Chadburn, Megan Lim, Gordan Srkalovic, Frits van Rhee, Sunita Nasta, Ariela Noy, Bridget Austin, Joshua Brandstadter, David Fajgenbaum Variable response rates across chemotherapy regimens for severe idiopathic multicentric Castleman disease , American Society of Clinical Oncology Annual Meeting, Chicago, IL.: 2025
